503 related articles for article (PubMed ID: 11772129)
21. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D
BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
[TBL] [Abstract][Full Text] [Related]
22. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).
Papatsoris AG; Karamouzis MV; Papavassiliou AG
Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy of the hormone-refractory prostate cancer].
Heine K; Wolff JM
Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
[TBL] [Abstract][Full Text] [Related]
24. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
25. Management of patients with hormone refractory prostate cancer.
Muthuramalingam SR; Patel K; Protheroe A
Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842
[TBL] [Abstract][Full Text] [Related]
26. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
[TBL] [Abstract][Full Text] [Related]
27. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
Sharifi N; Dahut WL; Figg WD
BJU Int; 2008 Feb; 101(3):271-4. PubMed ID: 17922868
[TBL] [Abstract][Full Text] [Related]
28. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
29. [Strategy in advanced castration-resistant prostate cancer].
Gross-Goupil M; Roca S; Pasticier G; Ravaud A
Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
[TBL] [Abstract][Full Text] [Related]
30. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
31. Recent progress in management of advanced prostate cancer.
Kantoff P
Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343
[TBL] [Abstract][Full Text] [Related]
32. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
33. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
34. Hormone-refractory Prostate Cancer.
Rini BI; Small EJ
Curr Treat Options Oncol; 2002 Oct; 3(5):437-46. PubMed ID: 12194808
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
36. The treatment challenge of hormone-refractory prostate cancer.
Kish JA; Bukkapatnam R; Palazzo F
Cancer Control; 2001; 8(6):487-95. PubMed ID: 11807418
[TBL] [Abstract][Full Text] [Related]
37. The management of hormone refractory prostate cancer.
Newling DW
Eur Urol; 1996; 29 Suppl 2():69-74. PubMed ID: 8717467
[TBL] [Abstract][Full Text] [Related]
38. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
Garcia JA; Rini BI
Cancer; 2012 May; 118(10):2583-93. PubMed ID: 22038761
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
[TBL] [Abstract][Full Text] [Related]
40. New therapies for castrate-resistant prostate cancer.
Williams SB; Lay AH; Lau CS; Josephson DY; Wilson TG; Choueiri TK; Pal SK
Expert Opin Pharmacother; 2011 Sep; 12(13):2069-74. PubMed ID: 21663529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
